与双相情感障碍相关的大型抑郁症发作的卢马特单疗法:在随机的安慰剂对照试验中的疗效和安全性
Christoph U Correll1,2,3,4, Suresh Durgam5, Susan G Kozauer5
1Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks.
International clinical psychopharmacology
|July 22, 2025
概括
这项研究发现,与安慰剂相比,卢马特佩龙并没有显著改善双极性抑郁症症状. 然而,在双极性抑郁症患者中,这两种lumateperone剂量都是安全的,并且耐受性很好.
科学领域:
- 精神病学是一个精神病学.
- 临床药理学 临床药理学
背景情况:
- 双极性抑郁症显著影响患者的幸福感.
- 需要有效和安全的治疗双极性抑郁症.
研究的目的:
- 在3期临床试验中评估lumateperone在治疗双极性抑郁症方面的疗效和安全性.
主要方法:
- 一个随机的,双盲的,安慰剂控制的研究.
- 18-75岁的双相I或II型抑郁症患者接受了卢马特佩龙 (28mg或42mg) 或安慰剂6周.
- 主要终点:蒙哥马利-阿斯伯格抑郁评分表 (MADRS) 评分的变化.
主要成果:
- 无论是lumateperone剂量,都没有在初级 (MADRS得分) 或关键次要 (持续响应的时间) 终点上显著地改善了安慰剂.
- 较高的安慰剂反应率可能影响了结果.
- 卢马特佩龙耐受性很好,外皮拉米德症状风险低,代谢变化最小.
结论:
- 在这项针对双极性抑郁症的研究中,卢马特没有达到主要的疗效目标.
- 两剂卢马特佩龙都显示出良好的安全性和耐受性.
相关概念视频
Mania and Antimanic Drugs: Overview
322
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
322
Antidepressant Drugs: MAOIs and Other Agents
366
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
366
Bipolar Disorder
145
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
145
Electroconvulsive Therapy
198
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
198
Depressive Disorders: MDD and Dysthymia
219
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
219
Psychosis: Goals of Pharmacotherapy
210
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
210


